Astellas Pharma, Inc. (4503) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.64 M

Shareholding (Mar 2025)

FII

0.12%

Held by 3 FIIs

DII

99.88%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 6.28%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 42.73

With a growth in Net Profit of 81.96%, the company declared Very Positive results in Jun 25

With ROE of 3.35%, it has a very attractive valuation with a 1.67 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 3,078,237 Million (Large Cap)

P/E

50.00

Industry P/E

Dividend Yield

0.03%

Debt Equity

0.45

Return on Equity

5.50%

Price to Book

2.08

Revenue and Profits:

Net Sales:

505,794 Million

(Quarterly Results - Jun 2025)

Net Profit:

68,422 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

22.05%

6 Months

44.48%

1 Year

29.58%

2 Years

17.36%

3 Years

-4.12%

4 Years

15.25%

5 Years

37.17%

Astellas Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Astellas Pharma, Inc. Shows Strong Financial Growth Amidst Flat Performance

Astellas Pharma, Inc. has reported its financial results for the quarter ending June 2025, revealing a mixed performance characterized by notable growth in key profit metrics despite an overall flat financial performance. The company's operating profit reached an impressive JPY 157,307 MM, marking the highest level recorded, with an operating profit margin of 31.1%. This indicates a strong operational efficiency and profitability for the company during this period.

In addition to the robust operating profit, Astellas Pharma, Inc. also reported significant growth in its pre-tax profit, which surged to JPY 92,009 MM, reflecting an impressive year-on-year growth rate of 89.45%. This substantial increase highlights the company's ability to enhance its profitability before tax considerations.

The net profit for the quarter also demonstrated remarkable growth, ...

Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops to JPY 1,569.00

Astellas Pharma, Inc. saw a significant stock decline today, contrasting with the modest decrease in the Japan Nikkei 225. Over the past year, Astellas has underperformed, with a notable drop compared to the index's gains. Despite challenges, the company shows strong management efficiency metrics.

Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops 4.6%

Astellas Pharma, Inc. faced a significant stock decline today, contrasting with the broader market's performance. Over the past year, the company has seen a notable drop, despite a substantial increase in profits. Astellas maintains a strong EBIT to Interest ratio, reflecting its debt management capabilities.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.01%

EBIT Growth (5y)

-2.04%

EBIT to Interest (avg)

42.73

Debt to EBITDA (avg)

0.65

Net Debt to Equity (avg)

0.42

Sales to Capital Employed (avg)

0.74

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

261.05%

Pledged Shares

Institutional Holding

0.12%

ROCE (avg)

15.78%

ROE (avg)

6.28%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.67

EV to EBIT

12.39

EV to EBITDA

6.97

EV to Capital Employed

1.47

EV to Sales

1.66

PEG Ratio

0.17

Dividend Yield

0.04%

ROCE (Latest)

11.86%

ROE (Latest)

3.35%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 6.91% vs 26.17% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 81.96% vs 13.50% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "505,794.00",
          "val2": "473,124.00",
          "chgp": "6.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "157,307.00",
          "val2": "103,566.00",
          "chgp": "51.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5,898.00",
          "val2": "4,495.00",
          "chgp": "31.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "68,422.00",
          "val2": "37,603.00",
          "chgp": "81.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "216.50%",
          "val2": "112.70%",
          "chgp": "10.38%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 19.25% vs 5.60% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 197.72% vs -82.73% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,912,323.00",
          "val2": "1,603,672.00",
          "chgp": "19.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "454,804.00",
          "val2": "335,910.00",
          "chgp": "35.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14,349.00",
          "val2": "9,368.00",
          "chgp": "53.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-190,558.00",
          "val2": "-127,136.00",
          "chgp": "-49.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "50,747.00",
          "val2": "17,045.00",
          "chgp": "197.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "133.70%",
          "val2": "111.00%",
          "chgp": "2.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

505,794.00

473,124.00

6.91%

Operating Profit (PBDIT) excl Other Income

157,307.00

103,566.00

51.89%

Interest

5,898.00

4,495.00

31.21%

Exceptional Items

0.00

Consolidate Net Profit

68,422.00

37,603.00

81.96%

Operating Profit Margin (Excl OI)

216.50%

112.70%

10.38%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 6.91% vs 26.17% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 81.96% vs 13.50% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,912,323.00

1,603,672.00

19.25%

Operating Profit (PBDIT) excl Other Income

454,804.00

335,910.00

35.39%

Interest

14,349.00

9,368.00

53.17%

Exceptional Items

-190,558.00

-127,136.00

-49.89%

Consolidate Net Profit

50,747.00

17,045.00

197.72%

Operating Profit Margin (Excl OI)

133.70%

111.00%

2.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 19.25% vs 5.60% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 197.72% vs -82.73% in Mar 2024

All Annual Results

Company CV

About Astellas Pharma, Inc.

Astellas Pharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Astellas Pharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROE of 6.28%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 42.73

With a growth in Net Profit of 81.96%, the company declared Very Positive results in Jun 25

With ROE of 3.35%, it has a very attractive valuation with a 1.67 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Astellas Pharma, Inc. Shows Strong Financial Growth Amidst Flat Performance

Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops to JPY 1,569.00

Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops 4.6%

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Mar'25

About Astellas Pharma, Inc.

Company Coordinates